Tune-in today at 2:20 PM ET for Autonomix CEO Brad Hauser's presentation at the Webull Financial Corporate Connect Webinar Series: Biotech/Medtech. Register here: bit.ly/47uQ0YP $AMIX

Tune in today at 1:00 PM ET: Autonomix President and CEO Brad Hauser will participate in a virtual investor webinar hosted by Ladenburg Thalmann. For registration: bit.ly/4fRmAGD $AMIX

Our CEO Brad Hauser will be participating in the LIVE! Biotech & Medtech Investment Webinar Week, happening soon Hear firsthand how we are driving innovation in precision-guidance technology to improve patient care Access the event here: bit.ly/3Hvo9NL Webull

⏰ Starting Soon! Don’t miss the Ladenburg Fireside Chat with Autonomix CEO, Brad Hauser, as he discusses what’s next for $AMIX. Access the event here: bit.ly/4ly7CXh #PainManagement #MedTech #Electrophysiology

Get the latest updates from Autonomix delivered straight to your inbox — including news, events, and investor updates. 📩 Sign up for email alerts today: bit.ly/3UTPr3d $AMIX #PainManagement #MedTech #Electrophysiology

#DidYouSee: We were recently granted a new U.S. patent (No. 12,295,646) for our innovative catheter device with “Smart Torque” IP protection. This patent strengthens our commitment to advancing nerve-focused treatments for high-need conditions. $AMIX

First-Hand Perspectives: Physicians & Patients Real voices. Real impact. In our PoC 1 study, hear directly from the primary investigator and patients as they reflect on their experiences and the potential of this breakthrough technology to change lives. bit.ly/3Htpepk

Brad Hauser, Autonomix CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. A video webcast of the presentation will be accessible for viewing on-demand. For details: bit.ly/45IjilG $AMIX

Autonomix today announced new longer-term post hoc data from its initial trial phase of its first-in-human PoC study evaluating the delivery of transvascular energy to ablate nerves and mitigate pain in patients with severe pancreatic cancer pain. bit.ly/3K4DVQo $AMIX

Brad Hauser, CEO of Autonomix, comments on new longer-term post hoc data from Autonomix's initial trial phase of its first-in-human study proof-of-concept study: bit.ly/3K4DVQo $AMIX

New longer-term post hoc analysis results of responders in Autonomix's PoC 1 study showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain. Read more: bit.ly/3K4DVQo $AMIX

Dr. Robert Schwartz, Autonomix CMO, discusses the recently announced results from the post hoc analysis of Autonomix's PoC 1 human clinical trial in a new Virtual Investor Co. “What This Means” segment. Watch it here: bit.ly/42Vr0q2 $AMIX

Autonomix joined a What This Means segment, where CMO Dr. Robert Schwartz highlighted PoC1 results showing sustained pain reduction, improved quality of life, and 100% zero opioid use. Watch here: vimeo.com/1115786041/191… $AMIX @autonomixmed

The longer-term post hoc data from Autonomix's PoC 1 study demonstrated sustained pain reduction, quality of life gains and 100% zero opioid use. Learn more: bit.ly/3K4DVQo $AMIX

In a new Virtual Investor Co. "What This Means" segment, Autonomix CMO Dr. Robert Schwartz discussed longer-term post hoc analysis from our PoC 1 trial, which demonstrated sustained pain reduction, quality of life gains, and 100% zero opioid use. Watch: bit.ly/42Vr0q2 $AMIX

Now available: Watch Autonomix CEO Brad Hauser's recent presentation at the H.C. Wainwright 27th Annual Global Investment Conference, held in New York, NY: bit.ly/4gamvhg $AMIX

Autonomix's technology and findings from the first phase of its first-in-human PoC study will be featured in a podium presentation at the 2025 CIRSE Annual Congress being held September 13-17, 2025 in Barcelona, Spain. For details: bit.ly/3VHENgs $AMIX #CIRSE2025

We’re excited to share that our VP of Product Development, Marco Bedoya, will be presenting at #CIRSE2025 in Barcelona on September 15th. Looking forward to highlighting our innovation in electrophysiology and engaging with the global interventional radiology community. $AMIX

Marco Bedoya, Autonomix VP of Research and Development, will be presenting at the 2025 CIRSE Annual Congress in Barcelona, Spain on Monday, September 15th, from 4:15 PM - 5:15 PM CEST. For details: bit.ly/3VHENgs #CIRSE2025

Autonomix is protected by a rapidly expanding global IP portfolio, including 18 patent families and more than 120 issued or pending applications worldwide. We are safeguarding our breakthroughs while advancing the future of patient care. $AMIX #MedTech #Electrophysiology